Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
GLP-1 and Blood Pressure: What the Evidence Shows GLP-1 receptor agonists, primarily licensed for type 2 diabetes and obesity management, have demonstrated modest blood pressure-lowering effects in clinical trials
Semaglutide GLP-1 is administered as a once-weekly injection, making it a convenient option for long-term weight management
The prosecution concluded it was more successful at maintaining target glucose control than slow acting insulin glargine U100
Our research suggests younger adults could become the driving force behind the next phase of obesity treatment adoption
A cohort study found that GLP-1RAs were associated with a reduced risk of hepatic decompensation and mortality in individuals with type 2 diabetes cirrhosis (Yen et al., 2024)
The UK Medicines and Healthcare products Regulatory Agency issued safety guidance in 2024 requiring healthcare professionals to be aware of aspiration risk whilst emphasising individualised assessment [45]
